Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 19/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987273 | 0.89 | GLS (1.00) | GLSMAPK1HSD17B10 | |
| SCHEMBL14987537 | 0.82 | GLS (0.86) | GLSMAPK1HSD17B10 | |
| SCHEMBL21368799 | 0.79 | GLS (0.80) | GLSMAPK1HSD17B10 | |
| SCHEMBL21368796 | 0.76 | GLS (0.76) | GLSMAPK1HSD17B10 | |
| SCHEMBL20033181 | 0.75 | GLS (0.73) | GLSMAPK1HSD17B10 | |
| SCHEMBL14987619 | 0.73 | GLS (1.00) | GLSMAPK1HSD17B10 | |
| SCHEMBL20034588 | 0.72 | GLS (0.64) | GLSMAPK1HSD17B10 | |
| SCHEMBL14987102 | 0.69 | GLS (1.00) | GLSHSD17B10 | |
| SCHEMBL14987284 | 0.66 | GLS (0.79) | GLS | |
| SCHEMBL14987443 | 0.65 | GLS (1.00) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | GLS 1/4885MAPK1 2959/4885HSD17B10 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.